VEGFA and renal cell carcinoma: In view of the property of high immune infiltration as mentioned before, immune-checkpoint inhibitor (ICI)-based therapy is considered as the effective treatment of metastatic renal cell carcinoma (mRCC) [46], for moderate and higher risk RCC, dual ICI/ICI could be regarded as the optimal choice of first-line treatments, ICI combined with VEGF or other therapy is available, too [47].